HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs

The therapeutic efficacy of histone deacetylase inhibitors (HDACi) for hematologic malignancies and solid tumors is attributed to their ability to remodel chromatin, normalize dysregulated gene expression, and inhibit repair of damaged DNA. Studies on the interactions of HDACi with PARP inhibitors i...

Descripción completa

Detalles Bibliográficos
Autores principales: Valdez, Benigno C., Nieto, Yago, Yuan, Bin, Murray, David, Andersson, Borje S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564514/
https://www.ncbi.nlm.nih.gov/pubmed/36243940
http://dx.doi.org/10.18632/oncotarget.28278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564514/
https://www.ncbi.nlm.nih.gov/pubmed/36243940
http://dx.doi.org/10.18632/oncotarget.28278

Ejemplares similares